Drug Approval | December 28, 2024
Shilpa Medicare's Unit IV receives Eurasia GMP approval
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
The company has received the GMP Certification after successful closure of the inspection
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
The GMP certificate will allow the manufacturing site in Hervás, Cáceres to manufacture active ingredients for the pharmaceutical industry that is based on medicinal plants
This approval reflects company’s unwavering commitment that the quality assurance
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
This transaction is the third acquisition by three different Japanese players in this segment
Subscribe To Our Newsletter & Stay Updated
